Evidence map›Paper›PMID 40163071›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2025

Policymaker Perspectives on Implementation Determinants of Rapid ART and Same-Day PrEP in Seven Priority Jurisdictions for Ending the HIV Epidemic: A Multisite Qualitative Study.

Anna-Sophia Katomski, Ana Michaela Pachicano, Alithia Zamantakis, Nanette D Benbow, Cathleen Willging, Joseph G Rosen, Elena P Rosenberg-Carlson, Wilson Gomez, Alison B Hamilton, Jessica E Kassanits and 10 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Anna-Sophia KatomskiDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Ana Michaela PachicanoNorthwestern University Feinberg School of Medicine, Institute for Sexual and Gender Minority Health and Wellbeing, Chicago, IL.
Alithia ZamantakisNorthwestern University Feinberg School of Medicine, Institute for Sexual and Gender Minority Health and Wellbeing, Chicago, IL.
Nanette D BenbowNorthwestern University Feinberg School of Medicine, Institute for Sexual and Gender Minority Health and Wellbeing, Chicago, IL.
Cathleen WillgingPacific Institute for Research and Evaluation, Albuquerque, NM.
Joseph G RosenDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Elena P Rosenberg-CarlsonUCLA David Geffen School of Medicine, Center for HIV Identification, Prevention, and Treatment Services (CHIPTS), Los Angeles, CA.
Wilson GomezDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Alison B HamiltonDepartment of Psychiatry and Biobehavioral Sciences, UCLA David Geffen School of Medicine, Los Angeles, CA.
Jessica E KassanitsNorthwestern University Feinberg School of Medicine, Institute for Sexual and Gender Minority Health and Wellbeing, Chicago, IL.
Robin Gaines LanziUniversity of Alabama at Birmingham (UAB) Department of Health Behavior, School of Public Health, Birmingham, AL.
Joyce L JonesDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD.
Tequetta ValerianoYale School of Nursing, Orange, CT.
Russell A BrewerUniversity of Chicago Department of Medicine, Infectious Diseases and Global Health, Chicago, IL.
Aadia I RanaDivision of Infectious Diseases, University of Alabama at Birmingham (UAB) Heersink School of Medicine, Birmingham, AL; and.
Uyen KaoUCLA David Geffen School of Medicine, Center for HIV Identification, Prevention, and Treatment Services (CHIPTS), Los Angeles, CA.
Maile KarrisDivisions of Infectious Diseases & Global Public Health, UCSD Department of Medicine, San Diego, CA.
Jill BlumenthalDivisions of Infectious Diseases & Global Public Health, UCSD Department of Medicine, San Diego, CA.
Sheree R SchwartzDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Laura K BeresDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

Funding

Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Sung-Jae Lee · 1997 to 2026
$53.5M
Using Coincidence Analysis to Investigate Factors Affecting PrEP Initiation and Continuation in Southern ending the Epidemic CountiesP30MH062294 · NIMH · YALE UNIVERSITY · PI Trace S Kershaw · 2001 to 2026
$48.5M
Virology and Immunology Technology CoreP30AI117943 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Sahera Dirajlal-Fargo · 2015 to 2026
$38.4M
The Brown Initiative in HIV and AIDS Clinical Research for Minority CommunitiesR25MH083620 · NIMH · MIRIAM HOSPITAL · PI NUNN, AMY STEWART · 2008 to 2025
$3.7M
NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI094189NIAID NIH HHS P30 AI117943NIMH NIH HHS P30 MH058107NIMH NIH HHS P30 MH062294NIMH NIH HHS R25 MH083620
6 · The paper itself

Abstract

backgroundAlthough rapid antiretroviral therapy (ART) and same-day pre-exposure prophylaxis models (henceforth "rapid START") are feasible, acceptable, and cost-effective in various contexts, significant barriers have hindered their broader implementation and scalability in the United States. Ryan White-funded clinics are cornerstones for HIV services, yet strategies are urgently needed to facilitate equitable rapid START adoption across contexts. This study aimed to identify common factors influencing rapid START to inform strategies applicable throughout jurisdictional settings.

methodsThe Network for Implementation Science in HIV examined the current implementation of rapid START among diverse Ryan White Part A-D-funded organizations across seven Ending the HIV Epidemic jurisdictions across the United States. Semistructured interviews (n = 13) were administered from March 2023 to August 2024, with HIV leadership across jurisdictions to identify rapid START implementation determinants and strategies to catalyze rapid START delivery. Data were deductively analyzed using the Consolidated Framework for Implementation Research.

resultsProminent barriers to rapid ART implementation across settings included provider/patient hesitancy and awareness gaps, siloed care systems, and funding complexities. Prominent implementation facilitators included learning collaboratives, technology integration, and clear contracting language. Key constraints to same-day pre-exposure prophylaxis implementation included funding inequities and suboptimal client/patient awareness, whereas enablers included integrated care models, availability of starter packs, and medication-assistance programs.

conclusionsSeveral consistent key barriers and facilitators spanned multiple Ending the HIV Epidemic jurisdictions despite contextual differences (eg, Medicaid expansion). Collaborative efforts between system leaders and service providers were universally characterized as essential for equitable adoption and penetration of rapid START models.

Indexed as

Anti-HIV AgentsEpidemicsHIV InfectionsPre-Exposure ProphylaxisHumansQualitative ResearchUnited StatesAnti-HIV Agents

Identifiers

PMID40163071
PMCPMC12188016

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.